A recent study published by Dr. Jordan Verplank, Assistant Professor in the Department of Anatomy, Physiology, and Genetics at the Uniformed Services University of the Health Sciences (USU), and a team of scientists from USU, State University of Buffalo (New York), and Cyclerion Therapeutics, has identified a promising approach for treating hereditary peripheral neuropathies, specifically Charcot Marie Tooth disease types 1A (CMT1A) and 1B (CMT1B). By focusing on increasing levels of cyclic guanosine monophosphate (cGMP) – a signaling molecule involved in various biological processes – the study has shown potential improvements in myelination, nerve conduction, and motor coordination in mouse models affected by these conditions. The findings were published in Cellular and Molecular Life Sciences on October 14, 2024. 

Read More